IL17A and uveitis: Secukinumab, a human monoclonal antibody inhibiting IL-17A, has been approved for the treatment of psoriasis, psoriatic arthritis and ankylosing spondylitis and it is also being investigated as a potential treatment for noninfectious uveitis.[10]